ArticleBioengineered
Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections.
Article in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Preventative and therapeutic potential of animal milk components against COVID-19: A comprehensive review.Food science & nutrition · 2023Article
- Bovine colostrum and its potential contributions for treatment and prevention of COVID-19.Frontiers in immunology · 2023Review
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Recombinant expression of hen egg white lysozyme with the assistance of xylanase fusion partner inBioengineered · 2022Article
- Antiviral properties of whey proteins and their activity against SARS-CoV-2 infection.Journal of functional foods · 2022Review
- Role of milk glycome in prevention, treatment, and recovery of COVID-19.Frontiers in nutrition · 2022Review
- Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health.F1000Research · 2022Article
- Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.Antibiotics (Basel, Switzerland) · 2021Review
- Nonclassical antagonism between human lysozyme and AMPs against Pseudomonas aeruginosa.FEBS open bio · 2021Article
- A Facile Strategy for Fabrication Lysozyme-Loaded Mesoporous Silica Nanotubes from Electrospun Silk Fibroin Nanofiber Templates.Molecules (Basel, Switzerland) · 2021Article
- Enhancing the Thermo-Stability and Anti-Bacterium Activity of Lysozyme by Immobilization on Chitosan Nanoparticles.International journal of molecular sciences · 2020Article
- Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.Scientific reports · 2019Article
- Stability of Therapeutic Enzymes: Challenges and Recent Advances.Advances in experimental medicine and biology · 2019Review
- Selective permeability of mucus barriers.Current opinion in biotechnology · 2018Review
- Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa.Nature communications · 2018Article
- Stabilization of a Virus-Like Particle and Its Application as a Nanoreactor at Physiological Conditions.Biomacromolecules · 2017Article
- Review
- Genetically enhanced lysozyme evades a pathogen derived inhibitory protein.ACS chemical biology · 2015Article
- Fusion with a cell wall binding domain renders autolysin LytM a potent anti-Staphylococcus aureus agent.FEMS microbiology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
There is increasing urgency in the battle against drug-resistant bacterial pathogens, and this public health crisis has created a desperate need for novel antimicrobial agents. Recombinant human lysozyme represents one interesting candidate for treating pulmonary infections, but the wild type enzyme is subject to electrostatic mediated inhibition by anionic biopolymers that accumulate in the infected lung. We have redesigned lysozyme's electrostatic potential field, creating a genetically engineered variant that is less susceptible to polyanion inhibition, yet retains potent bactericidal activity. A recent publication demonstrated that the engineered enzyme outperforms wild type lysozyme in a murine model of Pseudomonas aeruginosa lung infection. Here, we expand upon our initial studies and consider dual therapies that combine lysozymes with an antimicrobial peptide. Consistent with our earlier results, the charge modified lysozyme combination outperformed its wild type counterpart, yielding more than an order-of-magnitude reduction in bacterial burden following treatment with a single dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.